Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 17Recruiting 10Terminated 5Unknown 3Not yet recruiting 3Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Genital Neoplasms, Male 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Adrenal Cortex Hormones × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT06751108 2024-12-27

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Seoul National University

Active not recruiting
2,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡